The Foundation Fighting Blindness Board of Directors is pleased to announce the appointment of Benjamin Yerxa, PhD, as FFB’s new Chief Executive Officer, effective immediately.
Dr. Yerxa brings over 20 years’ experience in biotechnology and drug development to his new role. He has broad experience translating research discoveries into clinical milestones and commercial products. Most recently he was the president and co-founder of Envisia Therapeutics, a company focused on developing novel ocular sustained delivery therapies for the front and back of the eye. Dr. Yerxa also gained extensive management experience at pharmaceutical and science organizations, including leadership positions at Liquidia Technologies, Clearside Biomedical, Parion Sciences, and Inspire Pharmaceuticals.
Dr. Yerxa holds 60 U.S. patents and has worked in multiple other disease areas, including pulmonary, cardiovascular, and HIV.
Dr. Yerxa was selected following a national executive search led by a subcommittee of the FFB Board of Directors, chaired by FFB Chairman David Brint, Treasurer Haynes Lea, and Director Warren Thaler.
“We are extremely excited to have Ben Yerxa join FFB as our new CEO,” David Brint said in a press release announcing the appointment. “Ben has the skills and experience, particularly in the areas of drug development and partnerships between researchers, industry, and venture capital, to help FFB complete its mission to eradicate blindness caused by gene mutations.”
Retina International congratulates Dr Yerxa on his appointment and looks forward to working with him in the fight to cure blindness. .